{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T07:19:33Z","timestamp":1794899973369,"version":"4.9.1"},"reference-count":41,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gut"],"accepted":{"date-parts":[[2025,7,15]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Quantitative hepatitis B surface antigen (qHBsAg) is an important biomarker in chronic hepatitis B (CHB).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Establish qHBsAg profiles to guide novel drug development.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Baseline qHBsAg profiles, longitudinal qHBsAg trajectories and predictors of HBsAg seroclearance were determined in a large CHB cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This study included 4287 patients with qHBsAg measurements between 2009 and 2020 (62.5% male; mean age 48.0; 45.2% on nucleos(t)ide analogues (NUC)) with median baseline qHBsAg of 630.8 (117.1\u20131875.5)\u2009IU\/mL. 3437 (80.2%), 2516 (58.7%) and 997 (23.3%) patients had baseline qHBsAg &lt;3000\u2009IU\/mL, &lt;1000\u2009IU\/mL and &lt;100\u2009IU\/mL, respectively (69.2%, 46.9% and 22.9% in treatment-na\u00efve; 93.4%, 73.0% and 23.6% in NUC-treated patients correspondingly). Among patients with recent qHBsAg measurements in 2018 (n=1593), 98.9%, 71.1% and 26.9% of patients had baseline qHBsAg &lt;3000\u2009IU\/mL, &lt;1000\u2009IU\/mL and &lt;100\u2009IU\/mL, respectively (99.3%, 67.1% and 34.2% in treatment-na\u00efve; 98.7%, 73.1% and 23.0% in NUC-treated patients correspondingly). Age (OR 1.019\u20131.049), hepatitis B e antigen positivity (OR 0.264\u20130.349) and HBV DNA (OR 0.675\u20130.832) were independent determinants of qHBsAg &lt;100\u2009or 1000\u2009IU\/mL, respectively (all p&lt;0.05). Among patients with serial qHBsAg measurements, the median qHBsAg reduction was 0.10 (0.02\u20130.27) log IU\/mL\/year. After median follow-up for 6.3 (5.7\u201314.3) years, 526 patients (12.3%) achieved HBsAg seroclearance. Baseline alanine aminotransferase\/qHBsAg ratio \u22650.27 independently predicted HBsAg seroclearance (HR 4.904, p&lt;0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In an endemic population, &gt;40% of patients with CHB have qHBsAg &gt;1000\u2009IU\/mL. These patients are unlikely to achieve spontaneous HBsAg seroclearance, but also have suboptimal responses to novel antivirals. Our data has important implications for novel antiviral development.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/gutjnl-2025-335219","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T18:25:10Z","timestamp":1754418310000},"page":"119-130","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Large-scale profile study on hepatitis B surface antigen levels in chronic hepatitis B: implications for drug development targeting functional cure"],"prefix":"10.1136","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7447-7539","authenticated-orcid":false,"given":"Rex Wan-Hin","family":"Hui","sequence":"first","affiliation":[{"name":"Medicine, The University of Hong Kong, Hong Kong, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor Kwan-Hung","family":"Wu","sequence":"additional","affiliation":[{"name":"Medicine, The University of Hong Kong, Hong Kong, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen Cheuk-Ying","family":"Ho","sequence":"additional","affiliation":[{"name":"Medicine, The University of Hong Kong, Hong Kong, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan Hin-Man","family":"Leung","sequence":"additional","affiliation":[{"name":"Medicine, The University of Hong Kong, Hong Kong, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew Shing-Hin","family":"Chung","sequence":"additional","affiliation":[{"name":"Medicine, The University of Hong Kong, Hong Kong, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9078-5005","authenticated-orcid":false,"given":"Danny Ka-Ho","family":"Wong","sequence":"additional","affiliation":[{"name":"Medicine, The University of Hong Kong, Hong Kong, Hong Kong"},{"name":"State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Fung","sequence":"additional","affiliation":[{"name":"Medicine, The University of Hong Kong, Hong Kong, Hong Kong"},{"name":"State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9012-313X","authenticated-orcid":false,"given":"Wai-Kay","family":"Seto","sequence":"additional","affiliation":[{"name":"Medicine, The University of Hong Kong, Hong Kong, Hong Kong"},{"name":"State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2266-3935","authenticated-orcid":false,"given":"Lung Yi","family":"Mak","sequence":"additional","affiliation":[{"name":"Medicine, The University of Hong Kong, Hong Kong, Hong Kong"},{"name":"State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7985-7725","authenticated-orcid":false,"given":"Man-Fung","family":"Yuen","sequence":"additional","affiliation":[{"name":"Medicine, The University of Hong Kong, Hong Kong, Hong Kong"},{"name":"State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,8,5]]},"reference":[{"key":"2026091505552158000_75.1.119.1","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-10-239"},{"key":"2026091505552158000_75.1.119.2","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan0241","article-title":"RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg","volume":"9","author":"Wooddell","year":"2017","journal-title":"Sci Transl Med"},{"key":"2026091505552158000_75.1.119.3","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1080\/17460441.2023.2192920","article-title":"Advances in determining new treatments for hepatitis B infection by utilizing existing and novel biomarkers","volume":"18","author":"Mak","year":"2023","journal-title":"Expert Opin Drug Discov"},{"key":"2026091505552158000_75.1.119.4","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000431"},{"key":"2026091505552158000_75.1.119.5","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13095"},{"key":"2026091505552158000_75.1.119.6","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1111\/jgh.16728","article-title":"Regression of liver fibrosis after HBsAg loss: A prospective matched case-control evaluation using transient elastography and serum enhanced liver fibrosis test","volume":"39","author":"Mak","year":"2024","journal-title":"J Gastroenterol Hepatol"},{"key":"2026091505552158000_75.1.119.7","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3350\/cmh.2022.0399","article-title":"Clinical practice guidelines and real-life practice on hepatocellular carcinoma: the Hong Kong perspective","volume":"29","author":"Hui","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"2026091505552158000_75.1.119.8","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3350\/cmh.2022.0448","article-title":"The role of different viral biomarkers on the management of chronic hepatitis B","volume":"29","author":"Mak","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"2026091505552158000_75.1.119.9","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s12072-012-9373-4","article-title":"Serum hepatitis B surface antigen (HBsAg) kinetics in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B","volume":"7","author":"Seto","year":"2012","journal-title":"Hepatol Int"},{"key":"2026091505552158000_75.1.119.10","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25718"},{"key":"2026091505552158000_75.1.119.11","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jhep.2024.03.022","article-title":"ALT to qHBsAg ratio predicts long-term HBsAg seroclearance after entecavir cessation in Chinese patients with chronic hepatitis B","volume":"81","author":"Leung","year":"2024","journal-title":"J Hepatol"},{"key":"2026091505552158000_75.1.119.12","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1080\/17474124.2023.2196405","article-title":"Chronic hepatitis B: a scoping review on the guidelines for stopping nucleos(t)ide analogue therapy","volume":"17","author":"Hui","year":"2023","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2026091505552158000_75.1.119.13","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/14728214.2022.2074977","article-title":"Assessing the developing pharmacotherapeutic landscape in hepatitis B treatment: a spotlight on drugs in phase II clinical trials","volume":"27","author":"Hui","year":"2022","journal-title":"Expert Opin Emerg Drugs"},{"key":"2026091505552158000_75.1.119.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2210027"},{"key":"2026091505552158000_75.1.119.15","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2022.0012"},{"key":"2026091505552158000_75.1.119.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2405485"},{"key":"2026091505552158000_75.1.119.17","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1016\/j.cgh.2019.09.038","article-title":"Efficacy of Lenvervimab, a Recombinant Human Immunoglobulin, in Treatment of Chronic Hepatitis B Virus Infection","volume":"18","author":"Lee","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026091505552158000_75.1.119.18","unstructured":"Wang G , Cui Y , Hu G , et al . HBsAg loss in chronic hepatitis b patients after 24-week treatment with subcutaneously administered pd-l1 antibody asc22 (envafolimab): interim results from a phase iib extension cohort. Presented at: The Liver Meeting 2023; 2023; Boston, US,"},{"key":"2026091505552158000_75.1.119.19","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.jhep.2024.06.027","article-title":"Phase Ib\/IIa randomized study of heterologous ChAdOx1-HBV\/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in virally-suppressed patients with CHB","volume":"81","author":"Tak","year":"2024","journal-title":"J Hepatol"},{"key":"2026091505552158000_75.1.119.20","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2024-333026"},{"key":"2026091505552158000_75.1.119.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.01.014"},{"key":"2026091505552158000_75.1.119.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.01.007"},{"key":"2026091505552158000_75.1.119.23","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1016\/j.jhep.2024.10.041","article-title":"Reply to: 'Prediction of HBsAg loss after cessation of entecavir therapy'","volume":"82","author":"Hui","year":"2025","journal-title":"J Hepatol"},{"key":"2026091505552158000_75.1.119.24","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1016\/j.jhep.2024.10.008","article-title":"ALT to qHBsAg ratio predicts HBsAg seroclearance in HBeAg-negative patients receiving Peg-IFN-\u03b1-based therapy","volume":"82","author":"Wang","year":"2025","journal-title":"J Hepatol"},{"key":"2026091505552158000_75.1.119.25","doi-asserted-by":"crossref","first-page":"e228","DOI":"10.1016\/j.jhep.2024.12.036","article-title":"Reply to: 'ALT to qHBsAg ratio predicts HBsAg seroclearance in HBeAg-negative patients receiving Peg-IFN\u03b1 based therapy'","volume":"82","author":"Hui","year":"2025","journal-title":"J Hepatol"},{"key":"2026091505552158000_75.1.119.26","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21669"},{"key":"2026091505552158000_75.1.119.27","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181ec173d"},{"key":"2026091505552158000_75.1.119.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.08.009"},{"key":"2026091505552158000_75.1.119.29","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.04.046"},{"key":"2026091505552158000_75.1.119.30","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26385"},{"key":"2026091505552158000_75.1.119.31","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-021-10223-5"},{"key":"2026091505552158000_75.1.119.32","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-015-9675-4"},{"key":"2026091505552158000_75.1.119.33","doi-asserted-by":"crossref","DOI":"10.1038\/ctg.2017.51","article-title":"Seven-Year Treatment Outcome of Entecavir in a Real-World Cohort: Effects on Clinical Parameters, HBsAg and HBcrAg Levels","volume":"8","author":"Lam","year":"2017","journal-title":"Clin Transl Gastroenterol"},{"key":"2026091505552158000_75.1.119.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.11.039"},{"key":"2026091505552158000_75.1.119.35","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jhep.2024.08.010","article-title":"Sequential Peg-IFN after bepirovirsen may reduce post-treatment relapse in chronic hepatitis B","volume":"82","author":"Buti","year":"2025","journal-title":"J Hepatol"},{"key":"2026091505552158000_75.1.119.36","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41392-023-01451-2","article-title":"Immunosenescence: molecular mechanisms and diseases","volume":"8","author":"Liu","year":"2023","journal-title":"Sig Transduct Target Ther"},{"key":"2026091505552158000_75.1.119.37","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.3350\/cmh.2024.0855","article-title":"Prospect of emerging treatments for hepatitis B virus functional cure","volume":"31","author":"Hui","year":"2025","journal-title":"Clin Mol Hepatol"},{"key":"2026091505552158000_75.1.119.38","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1002\/hep4.1708","article-title":"Risks and Benefits of Discontinuation of Nucleos(t)ide Analogue Treatment: A Treatment Concept for Patients With HBeAg-Negative Chronic Hepatitis B","volume":"5","author":"van B\u00f6mmel","year":"2021","journal-title":"Hepatol Commun"},{"key":"2026091505552158000_75.1.119.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2004.03.004"},{"key":"2026091505552158000_75.1.119.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.07.017"},{"key":"2026091505552158000_75.1.119.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2010.03.020"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2025-335219","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:56:21Z","timestamp":1789476981000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2025-335219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,5]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12,5]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/gutjnl-2025-335219"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2025-335219","relation":{},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,5]]}}}